Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study

PaperCitations, authors & open-access status

First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 11 citations, 2025 year and closed oa status.

11
Citations
2025
Year
closed
OA Status

Related on ScholarIQ

Shahm Raslan
Author
The Lancet Oncology
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Melanoma and MAPK Pathways
Topic
Cancer Immunotherapy and Biomarkers
Topic
470M+ articles · free account